丙型肝炎病毒全基因组测序用于基因分型与耐药检测的临床评估
本研究临床评估一种不依赖病毒基因型的HCV全基因组NGS流程,并与部分基因组Sanger测序比较。结果显示亚型一致率为98.7%(376/381),耐药相关替代的正负符合率分别为97.8%(95%CI 92.5-99.4%)和99.9%(95%CI 99.5-100.0%),该流程还可检测新亚型、混合、重组及短暂耐药突变,并区分再感染与复发。
要点
- NGS与Sanger测序的HCV亚型一致率为98.7%(376/381)。
- 耐药相关替代阳性符合率97.8%(95%CI 92.5-99.4%),阴性符合率99.9%(95%CI 99.5-100.0%)。
- NGS可识别新亚型、混合、重组、短暂耐药突变,并区分再感染与复发。
核心结论
- HCV全基因组NGS流程与Sanger测序在亚型和耐药相关替代检测上高度一致,并具备识别复杂感染场景的能力。
研究设计与样本
- 通过将HCV全基因组NGS流程的结果与部分HCV基因组的Sanger测序结果进行比较来评估性能。
主要发现
- Sanger测序与NGS之间病毒亚型一致率为98.7%(376/381)。
- 耐药相关替代检测的阳性符合率为97.8%(95%CI 92.5-99.4%),阴性符合率为99.9%(95%CI 99.5-100.0%)。
- NGS流程能够检测新亚型、混合、重组、短暂出现的耐药突变,并区分同一亚型再感染与复发。
关键数值与推荐
- 亚型一致率98.7%(376/381)。
- 耐药相关替代阳性符合率97.8%(95%CI 92.5-99.4%),阴性符合率99.9%(95%CI 99.5-100.0%)。
临床怎么用
- NGS可考虑用于无泛基因型抗病毒药物广泛可及的 settings、感染“罕见”亚型或一线治疗失败者,以及疑似再感染的病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We sought to evaluate clinically a hepatitis C virus (HCV) whole-genome, next-generation sequencing (NGS) pipeline that is agnostic to viral genotype. METHODS: Performance of the NGS pipeline was assessed through comparison of results with Sanger sequencing (SS) of partial HCV genomes. RESULTS: There was 98.7% (376/381) concordance for viral subtype between SS and NGS. The positive and negative per cent agreements for determination of resistance-associated substitutions were 97.8% (95% CI 92.5-99.4%) and 99.9% (95% CI 99.5-100.0%), respectively. The NGS pipeline was also able to detect novel subtypes, mixtures, recombinants, transiently occurring resistance mutations and distinguish re-infection with the same subtype from relapse. DISCUSSION: Particular scenarios where NGS may be used include settings without universal access to pan-genotypic antiviral regimens, those infected with a 'rare' subtype or who have been failed by first-line therapy, and in cases of suspected re-infection.
引用
- Bradshaw D, Bibby DF, Manso CF, et al. Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. Clin Microbiol Infect. 2021. PMID: 34245902. doi:10.1016/j.cmi.2021.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。